BAX stock: buy or sell?
December 6th, 2019
Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments.
Should I buy BAX stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading strategy that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Baxter International stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Baxter International stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 12 ratings published for BAX stock in the last month. The general sentiment of these ratings is bullish for BAX stock, with 10 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-26||Credit Suisse Group||Reduce||Outperform|
|2019-7-26||Credit Suisse Group||Reduce||Outperform|
|2019-7-26||BMO Capital Markets||n/a||Outperform|
|2019-6-26||Wells Fargo & Co||n/a||Outperform|
|2019-6-20||Piper Jaffray Companies||n/a||Overweight|
|2019-5-13||JPMorgan Chase & Co.||n/a||Overweight|
|2019-4-3||Wells Fargo & Co||n/a||Outperform|
|2019-4-15||Barclays||Equal Weight||Equal Weight|
|2019-2-1||Piper Jaffray Companies||n/a||Overweight|
BAX stock analysis
Baxter International grew a slightly fine 0.84% and closed at $83.17.
Baxter International grew a slightly fine 0.84% and closed at $83.17. Since price and SMA200d lines crossed up on Nov/13, BAX climbed $3.28 (4.11%). BAX broke out again over $82.65 after a 2.83% correction started on Nov/29. On September, BAX hit new all time highs, pushing higher previous ATH of $88.17 recorded on September. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Shares of Baxter International raised a decent 1.74% this week. Late October BAX plummed a chilling -13.87% in just one week.
Not so far away is the last price record Baxter International marked early September. Since price and SMA40w lines crossed up by mid November, BAX climbed $4.87 (6.22%). Since SMA20d and SMA40w crossed up early April, BAX price climbed $3.15 per share (3.94%).
BAX stock price history
BAX stock went public on October 27th, 1981 with a price of $0.001. Since then, BAX stock grew a inf%, with a yearly average of inf%. If you had invested right after BAX's IPO a $1,000 in BAX stock in 1981, it would worth $inf today.
1: Adjusted price after possible price splits or reverse-splits.
BAX stock historical price chart
BAX stock reached all-time highs on September with a price of $89.69.
BAX stock price target is $87.30Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We found 12 price targets for BAX stock posted in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-26||Raymond James||Raises Target||$84.00||$95.00||13.1%|
|2019-7-26||Credit Suisse Group||Reiterates||$84.00||$95.00||13.1%|
|2019-7-26||Credit Suisse Group||Raises Target||$84.00||$95.00||13.1%|
|2019-7-26||BMO Capital Markets||Raises Target||n/a||$95.00||-|
|2019-6-26||Wells Fargo & Co||Raises Target||$89.00||$91.00||2.2%|
|2019-6-20||Piper Jaffray Companies||Reiterates||$80.00||$90.00||12.5%|
|2019-5-13||JPMorgan Chase & Co.||Reiterates||$80.00||$88.00||10%|
|2019-4-3||Wells Fargo & Co||Reiterates||$80.00||$89.00||11.3%|
|2019-3-5||Morgan Stanley||Raises Target||$80.00||$83.00||3.8%|
|2019-2-1||Piper Jaffray Companies||Reiterates||n/a||$80.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince April, when Baxter International published its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will extend this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Baxter International annual revenues jumped a decent 5.36% to $11,127.00 million dollars from $10,561.00 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) rose a 7.81% to 14.60%. Baxter International fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Baxter International TTM sales up to March 2019 were $11,082.00 and earnings $1,582.00 M dollars. When comparing this TTM figures with the last reported annuality, we can review Baxter International business evolution since December 2018: Annual sales up to March, compared to lastest yearly report, remained stable a tight -0.40%. Regarding profit margin, Baxter International stayed stable -0.32% to 14.60%
|2013||$15,260 M||-||$2,010 M13.2%||-|
|2014||$16,671 M||9.25%||$2,497 M15.0%||24.23%|
|2015||$9,968 M||-40.21%||$968 M9.7%||-61.23%|
|2016||$10,163 M||1.96%||$4,965 M48.9%||412.91%|
|2017||$10,561 M||3.92%||$717 M6.8%||-85.56%|
|2018||$11,127 M||5.36%||$1,624 M14.6%||126.50%|
|TTM||$11,082 M||-0.40%||$1,582 M14.3%||-2.59%|
Quarterly financial resultsBaxter International reported $2,632.00 million in sales for 2019-Q1, a -7.36% decline compared to previous quarter. Reported quarter earnings marked $347.00 M with a profit margin of 13.18%. Profit margin stayed constant a 0.93% compared to previous quarter when profit margin was 12.25%. When comparing turnover to same quarter last year, Baxter International sales marked an ugly loss and decreased a -1.68%.
|2017-Q2||$2,610 M||-||$264 M10.1%||-|
|2017-Q3||$2,710 M||3.83%||$248 M9.2%||-6.06%|
|2017-Q4||$2,774 M||2.36%||$-71 M-2.6%||-128.63%|
|2018-Q1||$2,677 M||-3.50%||$389 M14.5%||-647.89%|
|2018-Q2||$2,842 M||6.16%||$343 M12.1%||-11.83%|
|2018-Q3||$2,767 M||-2.64%||$544 M19.7%||58.60%|
|2018-Q4||$2,841 M||2.67%||$348 M12.2%||-36.03%|
|2019-Q1||$2,632 M||-7.36%||$347 M13.2%||-0.29%|
Baxter International ownershipWhen you are planning to invest in shares of a company, it's worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Baxter International, 0.13% of all outstanding shares are owned by its staff.
Bearish positions for BAX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Baxter International:
|Market cap||$42.5 B||$70.4 B||$61.3 B||$16.1 B||$2.8 B|
|Total shares||510.6 M||270.0 M||1,390.0 M||292.5 M||146.5 M|
|Float shares||509.7 M||269.9 M||1,390.0 M||292.0 M||144.7 M|
|- Institutional holdings (%)||88.2%||87.5%||93.4%||92.4%||0.0%|
|- Insider holdings (%)||0.1%||0.3%||0.2%||0.3%||8.5%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, December 6th, 2019|
|Day range||$82.76 - $83.53|
|Average true range||$1.06|
|50d mov avg||$82.47|
|100d mov avg||$84.12|
|200d mov avg||$80.73|
Baxter International performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We chose Becton, Dickinson and, Boston Scientific, Cardinal Health, Halozyme Therapeutics, ICU Medical, Medtronic, Owens & Minor, Stryker, Thermo Fisher Scientific and Zimmer Biomet as the bechmarking frame for Baxter International stock.
|OMIOwens & Minor||0.00%||154.32%||2.91%|
|TMOThermo Fisher Sci...||7.17%||12.33%||34.35%|